167 related articles for article (PubMed ID: 18930104)
1. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Crespo-Facorro B; Roiz-Santiáñez R; Pérez-Iglesias R; Pelayo-Terán JM; Rodríguez-Sánchez JM; Tordesillas-Gutiérrez D; Ramírez M; Martínez O; Gutiérrez A; de Lucas EM; Vázquez-Barquero JL
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1936-43. PubMed ID: 18930104
[TBL] [Abstract][Full Text] [Related]
2. Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Roiz-Santiáñez R; Tordesillas-Gutiérrez D; Ortíz-García de la Foz V; Ayesa-Arriola R; Gutiérrez A; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2012 Oct; 141(1):22-8. PubMed ID: 22884754
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic drug effects on brain morphology in first-episode psychosis.
Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
[TBL] [Abstract][Full Text] [Related]
5. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Caseiro O; Martínez-Garcia O; Pardo G; Ramirez-Bonilla M; Pelayo-Terán JM; Vázquez-Barquero JL
J Psychiatr Res; 2011 Jun; 45(6):763-9. PubMed ID: 21106207
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ramirez-Bonilla M; Martínez-Garcia O; Pardo-Garcia G; Caseiro O; Pelayo-Terán JM; Vázquez-Barquero JL
J Psychopharmacol; 2011 Jun; 25(6):744-54. PubMed ID: 21292922
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Boettger S; Jenewein J; Breitbart W
Palliat Support Care; 2015 Aug; 13(4):1079-85. PubMed ID: 25191793
[TBL] [Abstract][Full Text] [Related]
8. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
9. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
10. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
13. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Ayesa-Arriola R; Rodríguez-Sánchez JM; Pérez-Iglesias R; Roiz-Santiáñez R; Martínez-García O; Sánchez-Moreno J; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
Psychopharmacology (Berl); 2013 Jun; 227(4):615-25. PubMed ID: 23455591
[TBL] [Abstract][Full Text] [Related]
14. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Crespo-Facorro B; Carrasco-Marín E; Pérez-Iglesias R; Pelayo-Terán JM; Fernandez-Prieto L; Leyva-Cobián F; Vázquez-Barquero JL
Psychiatry Res; 2008 Mar; 158(2):206-16. PubMed ID: 18243335
[TBL] [Abstract][Full Text] [Related]
16. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
Grover S; Kumar V; Chakrabarti S
J Psychosom Res; 2011 Oct; 71(4):277-81. PubMed ID: 21911107
[TBL] [Abstract][Full Text] [Related]
18. An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.
Hawkins PCT; Wood TC; Vernon AC; Bertolino A; Sambataro F; Dukart J; Merlo-Pich E; Risterucci C; Silber-Baumann H; Walsh E; Mazibuko N; Zelaya FO; Mehta MA
Hum Brain Mapp; 2018 Jan; 39(1):319-331. PubMed ID: 29058358
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Smesny S; Langbein K; Rzanny R; Gussew A; Burmeister HP; Reichenbach JR; Sauer H
Schizophr Res; 2012 Jul; 138(2-3):164-70. PubMed ID: 22516552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
